Abstract To date, symptomatic medications prevail as the mainstay of treatment options for Alzheimer's disease (AD). There have been tremendous investments made to increase the numbers of drugs approved and the targets engaged, in an effort to alter the disease course or pathophysiology of AD. Unfortunately, almost all studies have not met expectations and no new drug (beyond medical foods) has been approved for the treatment of AD in the last decade. This review is a comparison of novel AD therapies in the late phases of clinical testing, including recent high-profile clinical failures, and agents in development with relatively unexplored mechanisms of action, with a focus on their potential as therapeutic agents and their proposed advantages over the treatments currently in use.
Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder responsible for a significant and growing population of patients suffering from dementia, with a projected prevalence in the USA alone of 13.2 million patients by 2050 [1] . In post-mortem assessment of AD-afflicted brains, neuropathological hallmarks of the disease include aggregation of amyloid beta (Ab) in plaques and highly phosphorylated tau proteins in neurofibrillary tangles [2] . Prior to end-stage illness, patients with AD experience variable symptomatic trajectories, with a common element of progressive cognitive decline over a period of years. Dementia is the most prevalent symptom, but often patients also experience changes in mood, increases in aggression, agitation and psychosis, depleted physical ability and reduction in lifespan. AD is especially costly for the caregivers responsible for helping patients manage their disease, and as the number of people afflicted continues to increase in coming years, pressures on the support systems for these patients will also increase.
Current US FDA-approved and European Medicines Agency (EMA)-approved treatments for AD are limited to cholinesterase inhibitors (ChEIs) for patients with mild to moderate disease (with the exception of donepezil, which is also approved for moderate to severe disease), and the N-methyl-D-aspartate (NMDA) receptor partial antagonist memantine, approved for use in moderate to severe AD, in addition to being under investigation for efficacy in a wide variety of other neurological conditions, including, but not limited to, autism, Tourette syndrome, neuropathic pain and non-AD types of dementia [3] . These types of therapies have been shown to improve symptoms and may decrease the rate of cognitive decline, but there are currently no FDA-approved therapeutic approaches that either arrest decline or reverse neuronal damage caused by the disease. Additionally, while the EMA has similar standards for efficacy and safety as the FDA [4] , its approval speed is generally slower in terms of both initial and final reviews for new drug therapies. This means that internationally, the best options for patients with AD are what amount to temporary symptomatic reductions rather than anything approaching effective amelioration of AD pathology. There are at present several encouraging experimental therapy options in varying stages of clinical development, many of which are immunotherapies targeting Ab designed to enhance and facilitate Ab clearance from the brain [5] , but there have also been significant high-profile failures of drugs in late-stage clinical trials that could potentially alter the future landscape of novel treatment through their inefficacy. While treatments currently under investigation are valuable in that they stand to improve the dearth of disease-altering pharmacological therapeutic options, failures are worth taking note of for their potential to change the way drug efficacy, disease models, treatment administration and patient populations are accounted for in new development. The purpose of this paper is to detail recent therapeutic failures juxtaposed with treatment options that still exhibit potential as well as novel pathological models to exploit for benefit in the future, and to examine the commonalities of failed trials and their potential repercussions on studies in the future.
Data 
Pharmacological Properties

Cerebrolysin
Ò is a peptide-based neurotrophic and neuroprotective agent. The drug is created through a standardized enzymatic breakdown of purified brain proteins and comprises free amino acids. Cerebrolysin Ò is currently approved for use in 44 countries as a treatment for dementia and stroke and is in phase III trials in multiple countries in Europe [6] . Cerebrolysin Ò is analogous to brain-derived neurotrophic factors in that they act in both the central and the peripheral nervous systems to increase growth of new neurons and support existing ones and are thought to protect against Ab toxicity [6] . Its pleiotropic effects include neuroplasticity as well as neuroprotection [6] . Its therapeutic possibilities increase when combined with ChEIs to relieve symptomatic effects as well as to potentially impact disease course.
Therapeutic Efficacy and Tolerability
While Cerebrolysin
Ò is approved for use in Austria, China, Germany, Russia and South Korea, the FDA has yet to approve it for use in the USA. A 2011 study published in the European Journal of Neurology seeking to establish efficacy and safety of Cerebrolysin Ò in moderate to moderately severe AD concluded with positive results. Patients with AD in the trial received 100 ml intravenous infusions of Cerebrolysin Ò (10 ml diluted in saline, n = 32; 30 ml diluted in saline, n = 34; 60 ml diluted in saline, n = 35) or a 100-ml saline infusion for placebo control (n = 32) [6] . Primary efficacy criteria included the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog?) and the Clinician Interview Based Impression of Severity (CIBIC?) in a 24-week postbaseline assessment [6] . At 24 weeks, all three dose-level cohorts showed significantly improved global clinical function, with specific benefits varying with dosage level; improvements in cognition were seen with the 10-ml dose arm, improvements in initiation of activities of daily living were seen in the 30-ml arm, and improvement in neuropsychiatric symptoms were seen in the 60-ml arm [6] . There was no significant change for scores in Mini Mental State Examination (MMSE) and trail-making test secondary parameters. The authors indicated that larger trials are necessary to confirm benefit in more advanced cases of AD.
In this assessment, 133 patients with an MMSE of \20 were evaluated for safety. There were no adverse events (AEs) related to differences in dosage received by each cohort. Of the patients in the 10-ml cohort, 56.3 % experienced at least one AE, as did 47.1 % of patients in the 30-ml cohort, 62.9 % of those in the 60-ml cohort and 62.5 % of those receiving placebo. AEs with the most common incidence rate ([10 %) in the 10-ml group were depression, urinary tract infection and fever (each affecting 12.5 %); urinary tract infections were also experienced by 20.0 % of patients in the 60-ml group and 25.0 % of those in the placebo group [6] . No serious AEs were related to the study drug. No safety issues related to Cerebrolysin Ò were indicated by the study's conclusion. As a result of the relative success of this trial, Ever Neuro Pharma GmbH is moving forward with a phase IV study to compare the efficacy of Cerebrolysin Ò with that of donepezil (NCT01822951), set to begin in September 2013 [7] .
Masitinib
As a tyrosine kinase inhibitor, masitinib is thought to ameliorate AD symptoms by inhibiting the survival, migration and activity of mast cells and thereby reducing neuroinflammation. In a phase II, randomized, placebocontrolled study to determine if receiving masitinib in addition to a ChEI in doses of 3 or 6 mg/kg/day twice daily for 24 weeks showed improvement of ADAS-Cog scores from baseline, it was determined that rates of clinically significant cognitive decline were considerably lower with masitinib adjunct treatment than with placebo [7] . The mean treatment effect in terms of change in ADAS-Cog was 6.8 and 7.6 at weeks 12 and 24, respectively [7] . Masitinib shows potential as an additional therapy option in conjunction with typical treatment. The effect of mast cells in AD pathology are not well understood; pursuing treatment options that manipulate mast cell production in response to Ab presence could provide a novel symptomatic treatment for AD even if it is ineffective in terms of altering causal factors of AD.
TRx0237
Pharmacological Properties
TRx0237 is a tau protein inhibitor that is currently enrolling in phase III trials for safety and efficacy in the USA, Europe and Asia. TRx0237 is a modified version of Rember, an earlier compound that TauRx Therapeutics tested in relation to the treatment of AD [8] . The newer version of the drug is a stabilized and reduced form of methylthionine, which is thought to target tau tangles and tau protein precursors as well as early-stage tau oligomers, dissolving them and slowing or halting their harmful effects on cognition [8] .
Therapeutic Efficacy and Tolerability
To date, no data regarding the phase I and phase II trials of TRx0237 have been published. The rationale given by TauRx Therapeutics is that phase II data tend to not be meaningful in terms of ultimate outcome of the clinical process, and that the data regarding safety and efficacy that have been presented to regulating authorities in the USA, Europe and Asia have engendered enough confidence to secure a phase III trial as well as almost entirely private funding for the study [8] . TRx0237 is currently recruiting for a double-blind, placebo-controlled, parallelgroup safety and efficacy study in patients with mild and mild-to-moderate AD (identifier number NCT01689246). The primary endpoints are change from baseline of ADAS-Cog scores and safety parameter changes. Secondary endpoints are changes in activities of daily living and change in baseline MMSE scores. Two experimental arms will be receiving 150 mg/day and 250 mg/day, respectively.
Negative Late-Stage Trials
Bapineuzumab
Pharmacological Properties
Bapineuzumab is a humanized monoclonal antibody active in the nervous system and designed to limit Ab aggregation in the brain through binding and removal, ameliorating the damage that accumulated Ab does to neurons. Bapineuzumab operates through targeting the N-terminus and amino acid sequences 1-5 of amyloid plaques as opposed to soluble Ab or Ab monomers [9] . Anti-Ab passive immunotherapy approaches have been shown to be effective with regard to preventing Ab accumulation in the brains of AD model transgenic mice and have been shown to reverse cognitive decline in transgenic mice. In human trials, patients vaccinated with Ab peptide who produced anti-Ab antibodies exhibited a significantly protracted pace of cognitive decline than unvaccinated counterparts. Bapineuzumab is the first monoclonal antibody to demonstrably reduce total tau and statistically significantly reduce phosphorylated tau in the cerebrospinal fluid of patients compared with placebo, potentially indicating an impact on the neurodegenerative biomarkers downstream of Ab. When combined with lowered brain amyloid density, there is the indication that decreased phosphorylated tau pathology is linked to Ab plaque pathology, although it is presently unclear how.
Therapeutic Efficacy and Tolerability
Results of an 18-month phase II, double-blind, placebocontrolled, multiple ascending dose trial to assess safety, tolerability and efficacy in patients with mild to moderate AD were generally positive. Patients (n = 243) were randomized to receive one of four dosing levels of bapineuzumab (0.15 mg/kg [n = 31], 0.5 mg/kg [n = 33], 1.0 mg/kg [n = 30] or 2.0 mg/kg [n = 30]) or placebo (n = 110) through intravenous infusion every 13 weeks and then assessed at efficacy endpoints of change from baseline in ADAS-Cog, Disability Assessment Scale for Dementia (DAD), the neuropsychological test battery (NTB), the clinical dementia rating sum of boxes (CDR-SB) and in total brain volume as measured by magnetic resonance imaging (MRI) [9] . In apolipoprotein E (ApoE)-4 carriers, no significant differences from baseline occurred at the end of the study for any of the metrics used.
However, in pre-specified analyses, ApoE4 non-carrier subjects showed significant positive effect from bapineuzumab with regards to the ADAS-Cog, NTB and CDR-SB. Additionally, MRI analysis of participating patients indicated that cortical Pittsburgh compound B (PiB) retention was reduced as a result of bapineuzumab administration. In a study where patients were assigned to bapineuzumab (n = 20) or placebo (n = 8), there was an estimated mean 11 C-PiB retention ratio change of -0.09 (95 % CI -0.16 to -0.02; p = 0.014) from baseline to week 78 in the experimental group compared with the ratio change of 0.15 (95 % CI 0.02-0.28; p = 0.022) [9] . Additionally, the 11 C-PiB retention ratio change between the two groups was an estimated mean difference of -0.24.
Treatment with bapineuzumab has been linked to reports of amyloid-related imaging abnormalities (ARIA) including vasogenic oedema, sulcal effusions (ARIA-E), microhaemorrhages and haemosiderin deposits (ARIA-H). In order to evaluate associated risk factors during bapineuzumab treatment, 210 patients from two phase II trials and one open-label study were included in a risk analysis [9] . A total of 36 (17 %) of patients experienced ARIA-E during bapineuzumab treatment; of these, 78 % remained asymptomatic while eight reported AEs of headache, confusion, and neuropsychiatric and gastrointestinal symptoms [9] . ARIA-H was also experienced by 17 (47 %) of the patients with ARIA-E. ARIA-E frequency increased in ApoE4 carriers and with dose escalation of bapineuzumab [9] .
The only dose-related adverse effect in the phase II trial was also the most severe of the side effects reported during the study; 12 patients experienced temporary vasogenic oedema. Ten of these patients were ApoE4 carriers and two were non-carriers. As a result, the phase III study is not evaluating the largest (2.0 mg/kg) dose level, to be replaced with a 1.0 mg/kg dosage [9] .
The phase III trial of efficacy of intravenous bapineuzumab in mild-to-moderate AD patients who are carriers of ApoE4 did not meet either primary endpoint; there was no significant change in cognitive or functional performance. Additionally, the second phase III trial involving ApoE4 non-carriers failed to separate from placebo on any measure of cognition [10] . Currently, bapineuzumab is in a phase II, randomized, double-blind, placebo-controlled, multicenter study to determine safety and pharmacokinetics of subcutaneous administration in subjects with mild to moderate AD. Results are expected in 2014 [11] . TM   ) A phase III multinational trial for Dimebon TM , an inhibitor of cholinesterase and NMDA receptors potentially operating through apoptosis, was initiated after phase II studies showed positive clinical efficacy in addressing cognitive and behavioural decline. The mechanism of action of latrepirdine has been speculated upon, including being a weak ChEI and NMDA antagonist. In a phase III study of Dimebon TM as monotherapy to treat AD or in combination with memantine, the experimental cohort saw no statistically significant difference in cognitive function compared with the control cohort when assessed through ADAS-Cog and CIBIC-? measures [12] .
Latrepirdine (Dimebon
Solanezumab
Pharmacological Properties
Solanezumab is a humanized monoclonal antibody against Ab. Its binding is specific to the central region of soluble monomeric Ab, potentially allowing peptides in the brain to be drawn out through the blood and disposed of in the periphery. In phase II trials, solanezumab was shown to increase Ab 42 concentrations in plasma and cerebrospinal fluid, indicating that aggregated plaques were potentially flowing out of the brain into the periphery. Following assay analysis to determine that the primary endpoint of monoclonal antibodies binding to their target was met, solanezumab advanced to phase III study [13] .
Therapeutic Efficacy and Tolerability
The actual therapeutic benefit on cognition for solanezumab has not been established. In a 21-day phase II trial with 19 participants being administered single-dose infusions of solanezumab ranging from 0.5 to 10 mg/kg, there was no evidence of any adverse effects with the exception of chills during intravenous administration, but also no evidence of any cognitive efficacy [14] . Additionally, no data were available regarding whether or not the Ab plaques that had potentially been dissolved into plasma were excreted or degraded any more effectively than those still bound in the brain. Eli Lilly announced in September 2012 that neither cognitive nor functional endpoints were met in a series of phase III, double-blind, placebo-controlled trials. However, in pooled analyses, when the subjects with mild AD were analysed in a pre-specified pooled analysis of the combined studies, solanezumab treatment was associated with a 35 % reduction in the rate of decline compared with placebo [14] . In December 2012, Eli Lilly announced the launch in 2013 of a new large-scale phase III clinical trial testing solanezumab in populations with mild AD in light of the drug's apparent success with the mild disease subgroup in the more general phase III trials concluded in 2012; results are expected within 3 years.
Intravenous Immunoglobulin
Pharmacological Properties
IVIg is an intravenous infusion of naturally produced anti-amyloid antibodies that could potentially effect concentrations of central nervous system (CNS) and peripheral Ab and improve cognitive function. It has been shown that passive immunotherapy of Ab antibodies can reduce cognitive decline and decrease amyloid plaque disposition in the brain [15] . IVIg is procured from the blood plasma of healthy human donors. It has been used safely as a therapeutic intervention in hundreds of thousands of patients since the first discoveries of its clinical benefits more than 30 years ago, and is already an FDAapproved treatment for a wide variety of immunodeficiencies in adults and children, including, but not limited to, Guillain-Barré syndrome, lupus erythematosus, Kawasaki disease, autoimmune haemolytic anaemia, immune thrombocytopenia and paediatric HIV [15] . Additionally, there are dozens of off-label uses for IVIg, including treatment of chronic lymphocytic leukaemia, multiple myeloma, muscular dystrophy and multiple sclerosis.
IVIg was proposed as a treatment in the category of immunotherapy. IVIg has been shown to contain natural anti-Ab antibodies, making it viable for development as a potential novel protein therapeutic in the treatment of AD. Corroborating results have been produced indicating the ability of IVIg to decrease cerebrospinal Ab and increase MMSE scores by 2.5 points after 6 months of treatment [15] . IVIg is administered as plasma protein replacement therapy to improve antibody production in immune-compromised patients, or in the case of AD patients to provide passive antibodies against Ab proteins determined to occur naturally in IVIg proteins [15] . Though both passive and active immunotherapeutic strategies have proven effective in animal models, the exact mechanisms for efficacious use of antibodies in combating Ab are not completely clear [15] .
Hypotheses for mechanisms of action include microglial-mediated phagocytosis, peripheral sink and inhibition of fibrillogenesis and cytotoxic Ab species. Transgenic models show microglial phagocytosis is initiated following the passive administration of antibodies, wherein antibodies entering the CNS to bind to Ab fibrils recruits microglia to phagocytose the compound through immunoglobulin G Fc receptor ligation and ultimately clear Ab out of the CNS, though non-Fc mechanisms such as scavenger receptors have been implicated in other studies [16] . The peripheral sink hypothesis operates on the necessity of maintaining equilibrium between CNS and peripheral plasma concentrations of Ab. Sequestering plasma Ab through administration of antibodies evokes a transportation of Ab out of the brain to maintain equilibrium, therefore decreasing CNS amyloid load. Inhibition of fibrillogenesis and cytotoxic Ab species could result in disaggregation of Ab plaques through binding the N-terminus of Ab, binding existing fibrils and preventing in vitro aggregation of new ones [16] . These mechanisms could each operate individually or in concert for novel treatment of AD or prevention thereof.
Therapeutic Efficacy and Tolerability
Results of the phase I trial for safety and preliminary efficacy indicated that all of the seven patients who participated in 6 months of therapy experienced a cessation in cognitive decline, and six of the seven experienced improved cognitive functioning from baseline as evaluated by the ADAS-Cog, with a mean improvement of 3.7 ± 2.9 points [16] . Total Ab in cerebrospinal fluid was reduced by 17.3-43.5 %. Phase II results presented at the AAIC in July 2012 indicated that IVIg has the potential to reduce both brain atrophy and cognitive decline [16] . In a 3-year extension study of the phase II IVIg trial, 16 originally enrolled subjects completed 36 months of treatment with IVIg at doses of 400 mg/kg every 2 weeks [16] . Participants in the experimental arm for the full 36 months showed no decline with regards to comparison at baseline of scores on the ADAS-Cog, Clinical Global Impression of Change (CGIC), Modified Mini Mental State (3MS), Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL), Neuropsychiatric Inventory (NPI,) or quality of life (QOL) at the 3-year mark [16] . Additionally, participants originally in the placebo arm who switched to IVIg treatment (n = 5) experienced less rapid decline following IVIg administration compared with typical decline on placebo [16] .
Because this therapy is derived from donated blood, it carries a risk of disease transmission, but there have been no reported cases of diseases transmitted through IVIg in the last decade. Minor and infrequent side effects include chills immediately following administration and the potential for allergic reactions or possible risk for heart, lung or kidney AEs. Recently, the primary result of the GAP trial of 400 mg/kg of IVIg every 2 weeks for 18 months was reported as not beneficial in mild to moderate AD. Sub-analyses reported modest beneficial effects in the moderate subjects. The second study has been suspended pending further analysis.
Semagacestat and Avagacestat
Gamma secretase inhibitors (GSIs) were developed because they were able to block gamma secretase, one of the two enzymes that cleave amyloid precursor protein to produce Ab. GSIs were orally available, with good CNS penetration and blood-brain barrier permeability. Clinical experimentation of semagacestat was halted in phase III in 2010 after the experimental drug arm exhibited worse performance than the placebo arm in terms of endpoint benchmarks of activities of daily living and cognitive assessment during interim analysis [17] . Safety concerns were emerging within the experimental cohort at an excessive rate. These included, but were not limited to, increased incidence of neoplasms, particularly skin cancer, which might reflect the impact on notch receptors. Earlier, the phase II trial had shown target engagement by lowering cerebrospinal fluid and plasma Ab42 reliably in the 10-week study. Another GSI, avagacestat, did not move into phase III, but the results on phase II have not been reported.
Flurbiprofen (Tarenflurbil)
Development of flurbiprofen, a gamma secretase modulator, was discontinued after it was determined that its proposed mechanism of action of anti-inflammatory activity was ineffective at proposed therapeutic concentrations, possibly because it did not cross the blood-brain barrier [18] . In phase II studies, the primary endpoint on cognition was not met but post hoc assessment suggested a positive signal in mildest subjects receiving the highest dose. The phase III study administered high doses of the study drug to mild AD subjects to potentially exploit the advantage of a higher dose for early-stage patients. The treatment group failed to separate from placebo [18] . Further development for AD has been discontinued.
Tramiprosate
An Ab aggregation inhibitor operating through the inhibition of glycosaminoglycans (GAGs), tramiprosate was initially proposed to prevent Ab disposition in the brain by preventing protein aggregation. Phase II showed a modest signal of efficacy but these findings were not recapitulated in phase III. Study of tramiprosate was discontinued due to failure to induce any cognitive improvement as well as causing moderately severe gastrointestinal side effects [19, 20] .
EGb 761
EGb 761 is an extract of Ginkgo biloba marketed in France for patients with mild AD and other memory disorders and approved in Europe, Asia and Latin America for treatment of cognitive disorders and mental function impairment. It is currently in phase III development in Germany for the treatment of AD. The utility of G. biloba as an herbal cognitive therapy is dubious. In a 2008 study to determine whether G. biloba slows the rates of global or domainspecific cognitive decline in older adults, it was determined that there was no difference in slowing cognitive decline between G. biloba and placebo [21] . In a randomized, double-blind, placebo-controlled clinical trial of 3,069 participants over 6 years, patients received either a twice daily dose of 120-mg extract of G. biloba (n = 1,545) or identical placebo (n = 1,524) [21] . Measures of outcome included rates of change for MMSE scores, change in ADAS-Cog scores, and in assessment of z scores of individual tests regarding memory, attention, visual-spatial construction, language and executive functions. Despite widespread marketing campaigns related to the ability of G. biloba to enhance or improve memory, the study concluded that G. biloba had no effect on either subtle preclinical cognitive changes associated with dementia or the cognitive changes associated with typical aging [21] . These results are supported by previous findings of the failure of G. biloba to affect cognition in any meaningful way; this therapeutic technique does not hold much promise in terms of experimental value.
Emerging Therapies
Docosahexaenoic Acid
Docosahexaenoic acid (DHA) is a long-chain polyunsaturated fatty acid found abundantly in the brain. Animal studies demonstrated a link between oral intake of DHA and reduction of brain pathology similar to that of AD in humans. In a 2010 randomized, double-blind, placebocontrolled trial of DHA supplementation in patients with mild to moderate stage AD, it was determined that DHA provided no benefit compared with placebo in terms of slowing the rate of cognitive decline and functional decline for mild to moderate disease [22] . No change in ADASCog score was seen between groups for 295 individuals who completed the trial while taking the supplement or placebo (n = 171 and n = 124, respectively). The rate of brain atrophy was not affected by DHA [22] . Mean brain volume decline was 24.7 cm for the DHA treatment group compared with a decline of 24.0 cm for placebo patients [22] . Though patients with severe AD were not treated, the potential for DHA to be a beneficial therapy continues to be investigated in different populations.
INM 176
Among novel therapeutic options with realistic potential for further development is INM 176, an extract of Angelica gigas. INM 176 is widely available as a dietary supplement and has completed phase III trials for efficacy in 2011, the results of which have yet to be released. Traditionally, A. gigas has been used in Eastern herbal medicine for its sedative effects and to treat anaemia, but it also shows promise for its anti-amnestic effects. In 2012 animal trials, scopolamine was used to induce memory impairments in mice. The effect of INM 176 was measured using passive avoidance, Morris water maze tasks, and levels of acetylcholinesterase activity as well as cholinergic neural loss [23] . Even a single administration of INM 176 was shown to significantly decrease memory impairment in water maze tasks and to counteract the memory impairment induced by presence of Ab (1-42) protein. The therapy also reduced astrocyte activation in the hippocampus [23] . These results warrant further investigation into development of INM 176 as a symptomatic treatment option.
ELND005
ELND005 is a stereoisomer of inositol found naturally occurring in some varieties of plants. Phase II trials of ELND005 required modification mid-trial after 5 % of all high-dose (1,000 and 2,000 mg twice daily) patients died while undergoing treatment [24] , and others experienced high rates of AEs (though Elan has not released specifics about what those AEs were). Though lower doses were approved for safety, the approved dose of 250 mg twice daily did not achieve co-primary outcome measures of improved NTB or ADCS-ADL scores [24] . This dose was sufficient to achieve cerebrospinal fluid drug levels associated with therapeutic results in animal models, so effects on clinical endpoints could potentially be enhanced in the future with continued study. In addition to effects on traditional AD symptoms, ELND005 is also under investigation as of fall 2012 for treatment of aggression and agitation in AD patients.
SKPC-B70M
SKPC-B70M is an extract of oleanolic-glycoside saponins from Pulsatilla koreana responsible for protecting Ab(1-42)-induced toxicity in SK-N-SH cells. In animal trials, it was shown that in scopolamine-induced memorydeficient rats, SKPC-B70M both improved memory function and reduced Ab levels and plaque deposition in the brain [25] . In Tg2576 AD model mice, insoluble and soluble Ab levels were reduced by 66 and 79 %, respectively, between 11 and 16 months of age, suggesting that SKPC-B70M can attenuate AD-like symptoms in Tg2576 model mice. Western plot analysis showed altered expressions for a variety of cellular factors, including up-regulation of transthyretin, phospho-ERK and phospho-CREB, suppression of neuronal toxicity induced by peroxide, and reduction of malondialdehyde and 4-hydroxy-2-nonenal in the hippocampus. The encouraging animal model results and the variety of potential positive effects make SKPC-B70M an adequate candidate for further development as a treatment option [25] .
RAGE Inhibitors
The receptor for advanced glycation endproducts (RAGE) has been implicated in AD pathology through its role as a binding site for Ab, the overproduction of which is linked to neuronal loss and dementia [26] . RAGE is part of an immunoglobulin supergene family member expressed in a multitude of cell types in both the brain and periphery, including the cells of the neurovascular compartment [27, 28] . RAGE has been hypothesized to contribute to AD pathology in a variety of methods, including promoting vascular leakage, promoting influx of peripheral Ab, and mediating Ab-induced oxidative stress and neural death [29] . TTP488 (TransTech Pharma, Inc.), an orally active, centrally acting antagonist of RAGE-RAGE ligand interaction, has been shown to significantly decrease the amyloid burden in the brains of transgenic mice [30] [31] [32] . Additionally, TTP488 has been associated with behavioural improvements such as reduction of distance traveled in the Morris water maze test, and with improvements in terms of normalizing electrophysiological recordings from hippocampal slices of treated mice [33] . Following successful phase I development, a primary phase II/III study met the futility endpoint [34] ; the results are expected to be reported in the immediate future.
BACE Inhibitors
Amyloidogenesis, the process by which Ab is produced, results from the consecutive endoproteolysis of amyloid precursor protein by b-and c-secretases. The amyloidogenic pathway is the preferred pathway in neurons and blood platelets while the non-amyloidogenic pathway is preferred in most other cells [35] [36] [37] , though brain inflammation may result in glial cells synthesizing Ab [38, 39] , as well as BACE1 [40] . Furthermore, these processing mechanisms provide several potential therapeutic targets to prevent the accumulation of Ab to pathological levels, such as inhibition of BACE1 activity. Several BACE inhibitors are in phase II trials, including LY2811376 and MK-8931, and are expected to move into phase III.
Insulin
The relationship between insulin dysregulation and the occurrence of AD pathology combined with the recent successful completion of a phase II study to determine the effects of intranasal insulin on mild memory loss makes it a strong candidate for early intervention therapy. In secondary analyses, the two treatment groups to receive doses of insulin had significantly less cognitive decline over the treatment period than the placebo group. Additionally, the treatment groups experienced less hypometabolism in the bilateral frontal, right temporal, bilateral occipital and right precuneus during the treatment period. The effects of insulin dysregulation on disease onset deserve more attention, as does the potential for insulin to keep memory loss at bay in mild-stage patients as well as therapeutic potential for other populations [41] .
Gantenerumab
Gantenerumab is another monoclonal antibody that has entered phase II/III clinical trials in the treatment of mild to moderate AD. It is the first fully human anti-AB monoclonal antibody [42] . It binds most strongly to aggregated forms and has been shown to reduce plaque. It has been shown to reduce cerebral amyloid 15-35 % [43] .
Discussion
These successes and failures have led to debate about the potential gaps in our understanding of the pathogenesis of AD, and potential pitfalls in the choice of therapeutic targets, development of drug candidates and design of clinical trials. Many clinical and experimental studies are ongoing, but we need to acknowledge that a single cure for AD is unlikely to be found and that the approach to drug development for this disorder needs to be reconsidered [44] . 2012 was a watershed year for AD therapeutics insofar as it continued the spate of failures in late-phase studies. Symptomatic treatments that are currently available can be realistically described as modest in benefit at best in terms of the actual, long-term benefits they provide patients and their families. The recent failures of solanezumab and bapineuzumab mark five large-scale, failed phase III drugs that had shown promise in phase II. Though solanezumab is being tested further in late-stage trials for subcutaneous administration and in mild disease populations, respectively, there is a reasonable chance these studies could yield disappointing results.
There is also the possibility that the disease is too entrenched to alter at the stages currently deemed to be the clinical priority. Potentially, amyloid might simply be the wrong target. Nevertheless, amyloid-based immunotherapies continue with gantenerumab and crenezumab in phase II studies. Regardless of the success or failure of IVIg in terms of improving cognition, in general the link between the amyloid pathology and clinical progression has not been well established. In fact, there is no evidence from clinical pathological or natural history studies that amyloid loads and clinical measures correlate, a finding that is reinforced by the recent results of bapineuzumab and solanezumab. That might be one reason that amyloid-based approaches have not yielded success or that they are being deployed too late.
Compared with amyloid-based therapy courses, many approaches related to other pathways are still in their infancy in terms of clinical development. Attention should be turned to developing strategies targeting non-amyloid approaches, such as those targeting tau, insulin, deep-brain stimulation (DBS) and transcranial magnetic stimulation (TMS). Therapies targeting the tau protein are promising for the breadth of approaches being developed. While there is currently no mutation of the tau protein associated directly with AD, tau dysfunction has been identified as responsible for a variety of neurodegenerative disorders all characterized by tau deposits. Additionally, more than 20 individual protein kinases, including glycogen synthase kinase 3 beta (GSK3beta), cyclin-dependent kinase 5 (cdk5) and microtubule-affinity-regulating-kinase (MARK), can effectively phosphorylate the tau protein. While this poses the problem of needing to narrow the field to determine which most contribute to hyperphosphorylation pathology, the opportunity exists to target kinases as a way of reducing protein aggregation [45] .
DBS and TMS have been used to diagnose and treat a variety of psychiatric and neurological disorders and are just recently gaining traction for AD application. DBS has been shown in the past year to increase brain cell glucose metabolism, a corollary to neuronal activity, by 20 % among six patients being treated with brain pacemakers after 1 year on a phase I study for safety (the primary outcome of which was met). In addition to reversing the decline of glucose metabolism typical for AD, the tentative success of this therapy option also gives credence to insulin as a treatment option to be hopeful about [46] .
A loss of metabolic ability prior to the onset of cognitive decline presents an intriguing path forward for research opportunities for an AD treatment. This is being explored through device (TMS and DBS) as well as through insulin and through medical foods.
Conclusions
In addition to the need for exploration into novel disease mechanisms not necessarily related to amyloid pathology, the pattern of success in middle-stage clinical trials with failure in phase III studies should be considered when approaching treatment. Overall, the field needs to be more circumspect and better informed. First, we need to consider that amyloid and many other treatments are being deployed too late. Second, animal models are largely misleading, giving a false-positive signal because animals have limited genetic makeups and very controlled environments. In contrast, humans are genetically, ethnically, temporally (age) and medically heterogeneous. The heterogeneity might confound or offset the effects of drugs that worked in animal models. Third, phase II studies have been largely misinformative. Many have small clinical signals, often discovered post hoc or have evidence of effects on biomarkers without evidence of robust clinical signals. Fourth, trial designs are currently blunt instruments. Cognitive measures are too reductionistic to measure the complexities of disease when most patho-biological changes have not been correlated or do not correlate with cognitive changes. Fifth, treatment will inevitably involve hitting multiple targets instead of a single target, but multi-target studies have not been conducted to date (above and beyond inclusion of symptomatic drugs).
